Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study.

Shogo Nakamoto Junichiro WatanabeShoichiro OhtaniSatoshi MoritaMasahiko Ikeda

Published in: BMC cancer (2022)

This study successfully identified subgroups of HER2- ABC patients with improved OS by eribulin therapy. Selecting patients according to their background and line of treatment will maximize the efficacy of eribulin therapy.

Keyphrases

metastatic breast cancer
end stage renal disease
chronic kidney disease
ejection fraction
phase ii
newly diagnosed
prognostic factors
clinical trial
cross sectional
patient reported outcomes
bone marrow
open label
double blind
free survival
placebo controlled
phase iii